Drug Trial Radar · NCT06016517
Application of the Personalized N-of-1 Trial Design in Patients With Rheumatoid Arthritis
Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
18
Planned (sponsor's estimate)
Start
Dec 1, 2026
Primary completion
Dec 1, 2028
Study completion Dec 15, 2028
Sponsor
- Lead sponsor
- Tufts Medical CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 29, 2023
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this N-of-1 study is to learn about treatment for individual patients who have rheumatoid arthritis (RA,) for which many treatments are available. The treatments are different in how they work, the way they are given, side- effects, and cost. While treatment guidelines are available, finding the best treatment order of treatments is often based on physician choice. The main question this study aims to answer are: * What are the effects of different treatments on RA symptoms and condition for each individual patient * What is the effectiveness of different treatments across all patients enrolled in the N-of-1 study Participants will be enrolled and randomized to a sequence of three U.S. Food and Drug Administration (FDA) approved RA medications: 1. etanercept, 2. adalimumab, 3. upadacitinib 4. tocilizumab. Participants will be asked to complete questionnaires about their condition and quality of life fortnightly, monthly and/or quarterly (either in clinic or remotely) and report their level of pain on alternate days (remotely).
Conditions
- Arthritis, Rheumatoid
Interventions
EtanerceptDrug
50 mg subcutaneously weekly
AdalimumabDrug
40 mg subcutaneously every 2 weeks
UpadacitinibDrug
15 mg orally once daily with subcutaneous placebo injection every 2 weeks
TocilizumabDrug
162 mg administered SQ every 2 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Disease Activity Score (DAS) 28Time frame: Baseline and week 12 of each treatment period
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Tufts Medical Center
Boston, Massachusetts · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.